See more : Appreciate Holdings, Inc. (SFRT) Income Statement Analysis – Financial Results
Complete financial analysis of Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jagsonpal Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- ERG Spólka Akcyjna (ERG.WA) Income Statement Analysis – Financial Results
- Clarke Inc. (CLKFF) Income Statement Analysis – Financial Results
- Netflix, Inc. (NFC.DE) Income Statement Analysis – Financial Results
- Sunrise Consulting Group, Inc. (SNRS) Income Statement Analysis – Financial Results
- Chemours Co (2CU.DE) Income Statement Analysis – Financial Results
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.jagsonpal.com
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.09B | 2.37B | 2.26B | 1.88B | 1.59B | 1.67B | 1.27B | 1.44B | 1.43B | 1.38B | 1.44B | 1.66B | 1.77B | 1.61B | 1.40B | 1.36B | 1.50B |
| Cost of Revenue | 1.43B | 931.04M | 961.06M | 809.34M | 562.31M | 729.32M | 612.95M | 589.50M | 591.23M | 686.83M | 647.06M | 861.62M | 845.46M | 830.00M | 755.02M | 789.03M | 913.06M |
| Gross Profit | 652.59M | 1.44B | 1.30B | 1.07B | 1.02B | 938.94M | 652.38M | 849.21M | 843.65M | 694.68M | 791.45M | 803.02M | 919.68M | 779.55M | 640.91M | 572.94M | 587.88M |
| Gross Profit Ratio | 31.27% | 60.67% | 57.49% | 56.92% | 64.54% | 56.28% | 51.56% | 59.03% | 58.80% | 50.28% | 55.02% | 48.24% | 52.10% | 48.43% | 45.91% | 42.07% | 39.17% |
| Research & Development | 0.00 | 0.00 | 0.00 | 3.46M | 1.54M | 1.21M | 3.74M | 5.64M | 4.69M | 3.29M | 5.55M | 6.93M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 38.05M | 57.64M | 101.73M | 40.69M | 8.97M | 14.97M | 6.93M | 0.00 | 93.72M | 0.00 | 452.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 163.36M | 186.08M | 153.18M | 129.90M | 178.45M | 131.98M | 112.46M | 0.00 | 109.96M | 0.00 | 38.55M | 38.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 438.55M | 243.72M | 254.90M | 170.60M | 187.41M | 146.94M | 119.39M | 345.64M | 203.67M | 334.23M | 604.96M | 615.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 57.34M | 1.78M | 3.57M | 758.19M | 1.32M | 646.06M | 808.04M | 1.00K | 633.38M | 15.00K | 2.91M | 3.21M | 653.65M | 500.95M | 428.17M | 472.45M |
| Operating Expenses | 438.55M | 1.11B | 1.05B | 881.55M | 945.60M | 854.42M | 765.45M | 808.04M | 750.56M | 633.38M | 712.92M | 729.56M | 778.89M | 653.65M | 500.95M | 428.17M | 472.45M |
| Cost & Expenses | 1.87B | 2.04B | 2.01B | 1.69B | 1.51B | 1.58B | 1.38B | 1.40B | 1.34B | 1.32B | 1.36B | 1.59B | 1.62B | 1.48B | 1.26B | 1.22B | 1.39B |
| Interest Income | 85.92M | 34.28M | 15.46M | 29.92M | 21.68M | 12.97M | 3.36M | 1.26M | 634.00K | 130.00K | 592.00K | 319.00K | 475.00K | 325.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.14M | 4.13M | 2.61M | 4.28M | 3.83M | 4.44M | 5.00M | 25.03M | 51.07M | 44.59M | 53.82M | 51.34M | 43.58M | 33.22M | 34.96M | 45.79M | 63.51M |
| Depreciation & Amortization | 16.63M | 11.75M | 15.26M | 10.86M | 11.30M | 10.16M | 3.20M | 19.94M | 30.94M | 27.07M | 28.25M | 27.08M | 25.36M | 22.01M | 20.85M | 12.50M | 16.87M |
| EBITDA | 323.46M | 363.96M | 284.53M | 234.72M | 110.59M | 107.64M | -103.41M | 190.36M | 124.66M | 88.37M | 107.39M | 103.77M | 169.84M | 147.91M | 160.81M | 153.64M | 128.62M |
| EBITDA Ratio | 15.50% | 16.85% | 12.38% | 12.31% | 6.90% | 6.27% | -7.95% | 4.24% | 8.56% | 6.40% | 7.42% | 6.04% | 9.41% | 9.19% | 11.52% | 11.55% | 8.81% |
| Operating Income | 214.04M | 338.85M | 239.87M | 187.86M | 74.03M | 83.19M | -111.27M | 143.97M | 40.75M | 16.72M | 25.30M | 22.45M | 97.69M | 92.68M | 105.00M | 98.99M | 51.92M |
| Operating Income Ratio | 10.26% | 14.31% | 10.61% | 10.00% | 4.67% | 4.99% | -8.79% | 10.01% | 2.84% | 1.21% | 1.76% | 1.35% | 5.53% | 5.76% | 7.52% | 7.27% | 3.46% |
| Total Other Income/Expenses | 84.65M | 9.23M | 20.97M | 30.86M | 20.12M | 5.51M | -3.21M | 104.28M | -52.33M | -44.45M | -53.33M | -48.18M | -40.04M | -30.62M | -31.33M | -39.45M | -57.28M |
| Income Before Tax | 298.69M | 348.09M | 273.19M | 218.72M | 94.15M | 90.03M | -116.27M | 143.97M | 40.75M | 16.72M | 25.31M | 25.36M | 100.90M | 92.68M | 105.00M | 98.99M | 51.92M |
| Income Before Tax Ratio | 14.31% | 14.70% | 12.08% | 11.64% | 5.94% | 5.40% | -9.19% | 10.01% | 2.84% | 1.21% | 1.76% | 1.52% | 5.72% | 5.76% | 7.52% | 7.27% | 3.46% |
| Income Tax Expense | 74.06M | 80.87M | 77.32M | 48.14M | 15.44M | 17.87M | -761.00K | 25.32M | 8.21M | 5.01M | 4.11M | 7.04M | 26.33M | 20.88M | 12.58M | 37.26M | 21.16M |
| Net Income | 224.63M | 267.21M | 188.55M | 170.58M | 78.71M | 72.16M | -115.51M | 118.65M | 32.54M | 11.71M | 21.21M | 18.33M | 74.57M | 71.80M | 92.42M | 61.72M | 30.76M |
| Net Income Ratio | 10.76% | 11.29% | 8.34% | 9.08% | 4.96% | 4.33% | -9.13% | 8.25% | 2.27% | 0.85% | 1.47% | 1.10% | 4.22% | 4.46% | 6.62% | 4.53% | 2.05% |
| EPS | 8.49 | 10.20 | 7.20 | 6.51 | 3.00 | 2.75 | -4.41 | 4.53 | 1.24 | 0.45 | 0.81 | 0.70 | 2.85 | 2.74 | 3.76 | 2.35 | 1.17 |
| EPS Diluted | 8.46 | 10.20 | 7.20 | 6.51 | 3.00 | 2.75 | -4.41 | 4.53 | 1.24 | 0.45 | 0.81 | 0.70 | 2.85 | 2.74 | 3.76 | 2.35 | 1.17 |
| Weighted Avg Shares Out | 26.46M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M | 26.19M | 26.20M | 26.20M | 26.20M | 26.18M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M |
| Weighted Avg Shares Out (Dil) | 26.55M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M | 26.18M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M | 26.20M |
Source: https://incomestatements.info
Category: Stock Reports